• BL-8040 Speeds Collection of Stem Cells for Transplant in Myeloma Patients, Phase 3 Data Suggest
  • Surface Oncology’s SRF231 Granted Orphan Drug Status for Treatment of Multiple Myeloma
  • Investigational Immunotherapy SRF231 Granted FDA Orphan Drug Status for Multiple Myeloma
  • CHMP Recommends Darzalex Combo Therapy for Certain Newly Diagnosed Multiple Myeloma Patients
  • Machine-learning Algorithm Predicts Responses to Myeloma Treatments
  • Urine Tests May Be Better Than Serum for Multiple Myeloma Screening, Study Suggests
  • Karyopharm Seeks Selinexor’s Accelerated Approval in US for Heavily Treated Myeloma Patients
  • Ninlaro Could Replace First-line Velcade in Older Myeloma Patients, Study Suggests
  • Dendritic Cell Vaccine in Immunotherapy Triple Combo Seen to Boost Immune Response to Myeloma in Early Study
  • Ninlaro Maintenance Therapy Fares Well in Phase 3 Multiple Myeloma Trial
  • Early Relapse in Multiple Myeloma Linked to Greater Economic Burden in US
  • Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows